公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

Applicant: ABBOTT LABORATORIES

Inventor： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC: A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC classification number: A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

Abstract: Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US20240116974A1

公开(公告)日：2024-04-11

申请号：US18345903

申请日：2023-06-30

Applicant: Primmune Therapeutics, Inc.

Inventor： Stephen E. WEBBER ,  James Richard APPLEMAN

IPC: C07H19/16 ,  A61K31/708 ,  A61K45/06

CPC classification number: C07H19/16 ,  A61K31/708 ,  A61K45/06

Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

公开(公告)号：US11850258B1

公开(公告)日：2023-12-26

申请号：US16887951

申请日：2020-05-29

Applicant: Nilesh B. Karalkar ,  Steven A. Benner

Inventor： Nilesh B. Karalkar ,  Steven A. Benner

IPC: A61K31/708 ,  C12P19/34 ,  A61K31/7072 ,  A61K31/7068 ,  A61K31/7076

CPC classification number: A61K31/708 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  C12P19/34

Abstract: This invention claims ribonucleosides and their derivatives, including triphosphates, that have a 3′-ONH2 moiety instead of a 3′-OH moiety.

公开(公告)号：US20230310469A1

公开(公告)日：2023-10-05

申请号：US18023600

申请日：2021-08-30

Applicant: Accencio LLC

Inventor： Kevin Brown ,  Kevin Brogle

IPC: A61K31/683 ,  A61K31/708 ,  A61K31/55 ,  A61K31/4375 ,  A61K31/522 ,  A61K9/00

CPC classification number: A61K31/683 ,  A61K31/708 ,  A61K31/55 ,  A61K31/4375 ,  A61K31/522 ,  A61K9/0014

Abstract: The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering a Toll-Like-Receptor (TLR) agonist, in particular a TLR-7 or TLR-8 agonist.

公开(公告)号：US11707508B2

公开(公告)日：2023-07-25

申请号：US16679425

申请日：2019-11-11

Applicant: ARES TRADING S.A. ,  Nicolas Chomont ,  Jean-Pierre Routy

Inventor： Alena Zalutskaya ,  John Gourley ,  Nicolas Chomont ,  Jean-Pierre Routy ,  Steven Deeks

IPC: A61K38/27 ,  A61P31/18 ,  A61K31/52 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/341 ,  A61K31/675 ,  A61K31/496 ,  A61K31/536 ,  A61K31/505 ,  A61K31/551 ,  A61K31/7072

CPC classification number: A61K38/27 ,  A61K31/341 ,  A61K31/496 ,  A61K31/505 ,  A61K31/52 ,  A61K31/536 ,  A61K31/551 ,  A61K31/675 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7072 ,  A61P31/18

Abstract: The subject invention pertains to methods of treating HIV-1 infected subject comprising the administration of growth hormone to a subject infected by HIV-1. The subject may be undergoing co-administration of anti-retroviral therapies (ARTs), may be untreated with anti-retroviral drugs (ARDs) or may be in a period of time where no ART is being administered. Growth hormone may be administered at a fixed dosage for a set period of time or may be administered at a first dosage for a first period of time that may then be increased or decreased to a second dosage for a second period of time.

公开(公告)号：US20230190876A1

公开(公告)日：2023-06-22

申请号：US17911891

申请日：2021-03-18

Applicant: GI INNOVATION, INC.

Inventor： Myung Ho JANG ,  Su Youn NAM ,  Young Jun KOH

IPC: A61K38/20 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00 ,  A61K39/395 ,  A61K31/4709 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/708 ,  A61K31/337 ,  A61K33/243 ,  A61K31/506 ,  A61K31/519

CPC classification number: A61K38/2013 ,  A61K38/1774 ,  A61K45/06 ,  A61P35/00 ,  A61K39/3955 ,  A61K31/4709 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/708 ,  A61K31/337 ,  A61K33/243 ,  A61K31/506 ,  A61K31/519

Abstract: A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.

公开(公告)号：US11633418B2

公开(公告)日：2023-04-25

申请号：US17242862

申请日：2021-04-28

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Michio Hirano ,  Caterina Garone

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/7072 ,  A61K31/708 ,  A61K31/7068 ,  A61K31/7076

Abstract: The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

公开(公告)号：US11591341B2

公开(公告)日：2023-02-28

申请号：US16849851

申请日：2020-04-15

Applicant: ALIGOS THERAPEUTICS, INC.

Inventor： Sandrine Vendeville ,  Pierre Jean-Marie Bernard Raboisson ,  Yannick Debing

IPC: C07D487/04 ,  C07D487/14 ,  C07D491/22 ,  A61K31/4985 ,  A61K31/551 ,  A61P31/20 ,  A61K31/675 ,  A61K31/683 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K38/21

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220313715A1

公开(公告)日：2022-10-06

申请号：US16306183

申请日：2017-05-29

Applicant: GIL MEDICAL CENTER

Inventor： Seung Kak SHIN ,  Oh Sang KWON ,  Myung Hee CHUNG

IPC: A61K31/708 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, comprising 8-OHdG or a pharmaceutically acceptable salt thereof, a method for preventing or treating liver fibrosis or liver cirrhosis using the same, and a food composition for ameliorating liver fibrosis or liver cirrhosis, comprising 8-hydroxydeoxyguanosine (8-OHdG) or a pharmaceutically acceptable salt thereof. As use of the pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis can reduce levels of various markers whose expression level increases due to induced liver fibrosis, the pharmaceutical composition can be widely used in the effective prevention or treatment of liver fibrosis or liver cirrhosis induced thereby.

公开(公告)号：US11439656B2

公开(公告)日：2022-09-13

申请号：US16556690

申请日：2019-08-30

Applicant: Regents of the University of Minnesota

Inventor： DaQing Yang ,  Carston R. Wagner ,  Aniekan Okon

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/708 ,  C07H17/02 ,  A61K31/426 ,  A61K31/365 ,  A61K47/68 ,  A61P35/00 ,  A61K31/675 ,  A61K31/196 ,  A61K31/197 ,  A61K31/175 ,  A61K31/495 ,  A61K31/366

Abstract: Described herein are small molecule cap-dependent inhibitors, including the compound of the formula: which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.